Purpose Abnormalities in lipid levels have been associated with colorectal neoplasm risk; however, few studies have adjusted for use of cholesterol-lowering medications. The objective of this study was to determine the association of plasma lipid levels with adenoma risk while accounting for statin medication use. Methods We included 254 subjects with advanced adenoma, 246 with single small adenoma, 179 with multiple small adenoma cases, and 403 control participants in the Tennessee Colorectal Polyp Study who also had plasma lipid measurements performed. Data on the use of statin medications were available for 83.4 % of these participants. The association between plasma lipids and adenoma risk was evaluated using logistic regression models.
Introduction
Diabetes mellitus and the metabolic syndrome are increasingly being recognized as risk factors for colorectal cancer [1, 2] . A prominent component of these metabolic abnormalities is dyslipidemia, defined as fasting triglycerides (TG) C150 mg/dl and high-density lipoprotein (HDL) \50 mg/dl (\40 mg/dl in men) [3] . Several prior studies have suggested that abnormalities in circulating lipid levels are associated with colorectal neoplasm risk [4] [5] [6] [7] [8] [9] [10] [11] . Although there have been inconsistencies, multiple studies have reported a direct correlation between triglycerides and risk of colorectal adenomas [4, 5, 7, 10, 12, 13] . Fewer studies exist which have examined other lipid fractions and their results have been mixed. Circulating low-density lipoproteins (LDL) have been reported as directly correlated [7, 11] or not correlated [10] with adenoma risk. Elevated HDL cholesterol levels have also been found to be associated with an increased [4, 7] , decreased [11, 14] , or no risk [5, 15] of colorectal neoplasm. These prior studies could be confounded by medication use as many individuals with dyslipidemia are treated with HMGCoA reductase inhibitors (statins), which might also have a direct impact on colorectal cancer risk [16] . The first statin medication was approved for sale in the USA in 1991; thus, studies published prior or around this date would not have needed to account for statin medication use; nevertheless, most studies investigating lipid fractions and colorectal adenoma risk have been published since the introduction of statin medications. To the best of our knowledge, no prior study has investigated the association between plasma lipids and adenoma risk after adjustment for use of statin medication.
Dyslipidemia could promote colorectal carcinogenesis through several mechanisms [17] . The metabolic pattern of increased triglycerides and reduced HDL cholesterol is also associated with insulin resistance, and increased circulating insulin/insulin-like growth factor-1 is associated with colorectal cancer risk [18] . Furthermore, increased LDL cholesterol could be associated with increases in oxidative stress, which in turn might promote neoplastic growth [19, 20] . Additionally, triglycerides impact bile acid secretion and may influence colorectal cancer risk through this mechanism [21] , and most of the biliary cholesterol derives from circulating HDL [22, 23] .
In this study, we investigated the association of plasma lipids with adenoma risk in a case-control study including 679 adenoma cases and 403 polyp-free controls. We collected detailed drug use information on a subset of this population to determine how use of statins might influence any associations.
Materials and methods

Participants
Participants were part of the Tennessee Colorectal Polyp Study, an ongoing colonoscopy-based case-control study being conducted in Nashville, Tennessee, USA. Study methods have been published elsewhere [24] . Briefly, eligible participants, aged between 40 and 75 years, were identified from patients scheduled for colonoscopy at the Vanderbilt Gastroenterology Clinic between 1 February  2003 and 29 October 2010 and at the Veterans' Affairs  Tennessee Valley Health System Nashville campus between 21 August 2003 and 30 May 2007 . Potential participants who had a genetic colorectal cancer syndrome (e.g., hereditary non-polyposis colorectal cancer or familial adenomatous polyposis) or a prior history of inflammatory bowel disease, adenoma, or any cancer other than nonmelanoma skin cancers were excluded. Among 12,585 eligible individuals, 7621 provided a written informed consent and participated in at least one component of the study (61 %). Seventy-six percent of participants (n = 5824) provided a blood sample, and of these plasma lipid levels were measured on 1318 participants (22.6 %). The study was approved by the Vanderbilt University Institutional Review Board, the Veterans' Affairs Institutional Review Board, and the Veterans' Affairs Research and Development Committee.
For the current study, we utilized case-control sets that had been previously identified as part of a study investigating urinary prostaglandin E 2 metabolite levels and adenoma risk [25] . Cases were classified into three case groups: single small adenomas (n = 248), multiple small adenomas (n = 204), and advanced adenomas (n = 285). Controls were matched to case groups by age (within 5 years), gender, and race (white/non-white). Additional matching criteria included at least one of the following criteria: sample collection date (within 90 days or season), study site (academic medical center/VA hospital), and regular use of NSAIDs (current, former or never). Out of 1,163 potentially eligible participants in this subset, we excluded 81 participants with missing smoking or alcohol use data. The current analyses included 246 single small adenomas, 179 multiple small adenomas, 254 advanced adenoma cases, and 403 polyp-free controls. The initial baseline study questionnaire did not capture information related to statin use, and this question was added in June 2004. Of the 1082 participants included in this analysis, 83.4 % (902) had data on statin medication use.
Outcome assessment
Patient colonoscopy results were recorded using standardized data-entry forms. Information on the number, location, and size of polyps were collected. Polyps were classified as an adenoma (which included villous, tubulovillous, tubular, sessile serrated, and traditional serrated on the basis of a histologic review), hyperplastic, mixed, or other. We additionally characterized cases as having a single small adenoma (\1 cm), multiple (two or more) small adenomas, and advanced adenomas. A polyp was considered an advanced adenoma if it met one of the following three criteria: (1) size C1.0 cm, (2) a [25 % villous component, or (3) contained a high-grade dysplasia.
Exposure assessment
A standardized telephone interview was conducted by trained interviewers following colonoscopy to obtain information on medication use, demographics, personal medical history, family history, reproductive history, anthropometry, and lifestyle. Participants completed a semiquantitative 108-item food frequency questionnaire (FFQ) which was developed to capture diet in the southeastern USA [26] . Seventy-eight percent (n = 5,906) of all study participants completed the FFQ.
Laboratory assays
Participants recruited prior to colonoscopy were asked to donate a 20-mL fasting blood sample. The blood was drawn into EDTA-containing, ACD-containing, and serum BD Vacutainer Ò tubes. EDTA tube blood was separated into plasma, buffy coats (white cells), and red blood cells. Samples were processed within 6 h of collection and stored for future analyses in -80°C freezer. Plasma samples from EDTA tube were used in this study. The levels of lipid biomarkers were measured by using the ACE Alera Ò Clinical Chemistry System (Alfa Wassermann, Inc., West Caldwell, NJ). The levels of triglycerides, total cholesterol, and HDL cholesterol were assayed using the ACE Ò Triglycerides Reagent (SA1023), Cholesterol Reagent (SA1010), and HDL-C Reagent (SA2038) (Alfa Wassermann, Inc., West Caldwell, NJ), respectively, following the manufacture's protocols. LDL cholesterol level was calculated with the Friedewald equation
In subjects with triglyceride levels above 400 mg/dL, the LDL cholesterol levels were measured directly using ACE Ò LDL-C Reagent (SA1040). The level of lipoprotein (a) was measured using lipoprotein (a) reagent set from Pointe Scientific, Inc. (Canton, MI) following the manufacturer's protocols.
Statistical analysis
We compared differences between case and control participants by using Wilcoxon rank-sum test for continuous variables or the Cochran-Mantel-Haenszel Chi-square test for categorical variables. Conditional logistic regression models were used to estimate risk of colorectal polyps associated with plasma cholesterol levels. Plasma lipids levels were categorized into quartiles on the basis of the distribution of the polyp-free control participants. All models were adjusted for age (continuous), body mass index kg/m 2 (continuous), regular alcohol use (current use, former use, or never used), cigarette use (current use, former use, or never used), regular physical activity in the past 10 years (yes or no), use of hormone replacement therapy (ever, never, or women only), indication for colonoscopy (screening or diagnostic), regular use of NSAIDs or aspirin (yes or no), and study site (Vanderbilt or VA). We constructed similar models restricting to individuals with statin medication information. We categorized statin users as either current users (n = 327) or never users/former users (n = 575). We calculated tests for trend by rank-ordering exposure categories and including the variable within the model as a continuous term. We constructed separate logistic regression models with a dependent variable of nonadvanced adenoma or advanced adenoma in comparison with controls. All statistical calculations were performed with SAS software (version 9.2; SAS Institute).
Results
The demographic and lifestyle data of the study participants are presented in Table 1 . Single small, multiple small, and advanced adenoma cases were older than controls (p value \0.0001), more likely to have a greater BMI (p value = 0.003), and more likely to use tobacco (p value \0.0001) and alcohol (p value = 0.02). Controls were less likely to report using statin medications (p value = 0.02).
For both men and women, there were no statistically significant differences seen between cases and controls for total cholesterol or LDL cholesterol (Table 2 ). For both men and women, HDL cholesterol was higher in controls (p value \0.0001 and 0.002 for men and women, respectively) and triglycerides lower in controls (p value = 0.005 and 0.003 for men and women, respectively) compared to cases. Lipoprotein (a) was higher in controls compared to cases for men (p value = 0.009) only.
We found no association between total cholesterol, LDL cholesterol, or lipoprotein (a) and single small, multiple small, or advanced adenomas (Table 3) . Increasing levels of HDL cholesterol were associated with a reduced risk of single small, multiple small, and advanced adenomas (p trend = 0.06, 0.02, and 0.0005, respectively). Participants in the highest quartile of HDL cholesterol had an adjusted odds ratio of 0.22 (95 % CI 0.09, 0.54) for an association with advanced adenoma risk compared to individuals in the lowest HDL quartile. Because HDL and triglyceride levels are inversely correlated, we also constructed similar models adjusting for triglyceride levels. These results were not substantially altered when mutually adjusting for triglycerides and HDL (data not shown). There was a statistically significant trend for increasing levels of triglycerides associated with increased risks of single small adenomas (p trend = 0.005) compared to controls. This trend remained significant when additionally adjusting for HDL levels. For advanced adenomas, participants in the highest quartile of triglycerides had an adjusted odds ratio of 2.79 (95 % CI 1.25, 6.23) for an association with advanced adenoma risk compared to individuals in the lowest triglyceride quartile.
To evaluate the accuracy of self-reported statin medication use, we compared LDL cholesterol levels between statin users (n = 327) and former or never statin users (n = 575). The median level of LDL was 96 mg/dl (IQR 76, 120) in statin users and 125 mg/dl (IQR 104, 148) in non-statin users (p \ 0.0001). When restricted to participants with information related to statin use and adjusted for statin medication use, there remained a trend toward a reduced association between HDL cholesterol levels and all adenoma types, which was statistically significant only for advanced adenomas (p trend = 0.0007; Table 4 ). When restricted participants with information related to statin 
Discussion
In this case-control study of colon adenomas, we found that higher levels of HDL cholesterol are associated with a reduced risk of multiple small and advanced adenomas and that this association is maintained after adjusting for statin use. Although the effect sizes suggested an inverse association between single small adenomas and HDL cholesterol levels, the trends were only of borderline statistical significance. We found that higher levels of triglycerides were associated with an increased risk of single small and advanced adenomas. This effect was less pronounced for multiple small adenoma cases. Our results confirm prior studies that have described an association between certain plasma lipids and colorectal neoplasm risk. Liu et al. [14] analyzed individuals who were diagnosed with metabolic syndrome based on the American Heart Association and National Heart Lung Blood Institute and found that men had a stronger correlation with metabolic syndrome and colorectal adenomas and that only central obesity, low HDL, and high triglycerides were independently associated with colorectal adenomas. Van Duijnhoven et al. [6] reported an inverse association between HDL cholesterol and colon cancer. In contrast to our study, plasma triglycerides were not statistically significantly associated with colon cancer. Otani et al. [13] showed there was a correlation between elevated triglycerides and colorectal adenoma, which was more pronounced in men than women. In a study including 1771 adenoma cases and 4667 control participants, plasma triglycerides greater than or equal to 150 mg/dL were associated with an odds ratio of 1.47 (95 % CI 1.06, 2.04) for advanced adenomas (n = 186) compared to participants with triglycerides \150 mg/dL [5] . Bird el al. [4] also reported higher triglyceride levels to be associated with adenoma risk.
We found no association between total cholesterol or LDL cholesterol in our primary analysis. We did find a positive association between increasing LDL cholesterol and single small adenoma risk; however, the effect was only found in the middle quartiles and only when our analysis was restricted to individuals with data on statin use. These findings are in contrast to some prior studies that have reported positive associations; however, other studies have not reported any association [6, 10] . We found a very strong inverse association between HDL cholesterol and adenoma risk. Prior studies investigating HDL cholesterol have found inverse associations [6, 11] , null associations [5, 15] , and positive associations [4, 7] . It is not clear why these findings have been so inconsistent with respect to HDL cholesterol. This may be related to study design, study population, and/or choice of outcome (adenoma versus colorectal cancer). With regard to adenoma risk, a cross-sectional study conducted in Korea found that increasing HDL levels correlated with increased prevalence of non-advanced adenomas, but no association was found with advanced adenomas [7] . A case-control study also conducted in Korea reported a nonsignificant trend for increasing adenoma risk with increasing HDL cholesterol levels [10] . A second cross-sectional study conducted in Germany found a decrease risk of colon adenomas with increased HDL cholesterol levels [11] . In our study, we demonstrated a very strong inverse association between HDL cholesterol and adenoma risk. These inconsistencies are challenging to address given the lack of mechanistic insights into how HDL may influence colorectal adenoma risk. However, one can speculate that the HDL connection with colon cancer may work both ways, with the inflammatory state caused by cancer as a depressing force for plasma HDL levels [28] , and the loss of anti-oxidant activity caused by low HDL states as a facilitating force for cancer development [29] . It would be interesting to study whether loss of HDL function without reductions in HDL levels, seen in subjects with end-stage renal disease [30] , is also associated with colon cancer. Interestingly, an increased risk of colorectal cancer in subjects with CKD was recently reported [31] . The strength of the inverse association between HDL and cancer in general is given by a recent meta-analysis of several controlled studies [32] . Strengths of the study include detailed information on statin use and a relatively large sample of advanced adenomas. In addition all study participants underwent complete colonoscopy examination. There are several limitations to the study. We were missing information on several important confounders such as personal history of diabetes mellitus, hypertension, and concomitant medication use. Second, although the dietary questionnaire was tailored for populations in the southeast USA, certain food combinations or preparations that are commonly consumed might have been unaccounted for. Another limitation was the lack of data on the duration of statin use. Studies of NSAID use and colorectal neoplasm risk have suggested that duration of use is an important factor to consider when investigating protective associations [33] . In addition, statin use was self-reported; however, we found that those reporting using statin medications did have lower LDL cholesterol levels which would suggest these participants were likely using the medications.
Conclusion
In conclusion, we found a direct association between triglyceride plasma levels and an inverse correlation between plasma HDL cholesterol levels and adenoma risk. Both effects appeared stronger in patients with advanced adenoma compared to those with single and multiple simple adenomas. These findings remained significant after adjustment for statin medication use. 
